Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.

Trial Profile

Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms IRMA
  • Most Recent Events

    • 25 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 25 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
    • 02 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top